Yatharth Hospital: Strong Healthcare Play at a Discounted Valuation?

🏥 Why Yatharth Deserves Attention Now: Yatharth Hospital is expanding rapidly, showing solid fundamentals—yet trades at a much lower P/E than sector peers. 📊 FY25 Snapshot: Revenue: ₹8,805 Mn (+31% YoY) PAT: ₹1,306 Mn (+14%) EBITDA: ₹2,202 Mn (Margin: 25%) Occupancy: 61% (↑ from 54%) ARPOB: ₹30,829 (+8%) Net Cash: ₹5,032 Mn Cash Conversion: 68% 📉 Valuation vs Peers: Company P/E ARPOB Occupancy Yatharth 38.9x ₹30.8K 61% Max Healthcare 106x ₹31K 76% Apollo Hospitals 77x ₹35K 64% Fortis Healthcare 67x ₹32K 67% ➡️ Despite robust numbers, Yatharth trades at a noticeable discount. 🚀 Growth Drivers: 700+ beds being added by FY26 in Delhi & Faridabad Oncology = 10% of revenue (3x YoY) ARPOB in Noida Extension at ₹38.8K (↑11%) Focused on North India expansion 💸 Financial Strength: EBITDA Margin: 25% Net Cash > ₹5,000 Mn FY25 Operating Cash Flow: ₹1,496 Mn Debt-light & capex-efficient model 📌 Technical Insight (Without Chart): Broke above a multi-month falling trendline (Nov–Apr) Retested ₹520 zone (old resistance) Sustained close above ₹525–530 may signal move toward ₹550+ Support lies in ₹480–485 zone (confluence area) 📍Key Level: ₹551.90 – overhead supply from January highs. 📢 Disclaimer: This is for informational purposes only. Nothing herein constitutes a buy or sell recommendation. I may or may not be holding a position in the stock mentioned. 🧑‍💼 Rajneesh Sharma is a SEBI-registered Research Analyst (Reg. No. INH000020332). 📄 Investments are subject to market risks. Read all related documents carefully before investing.